KR20010071832A - Ｎａｂ1 및 ｎａｂ2의 약학 용도 - Google Patents

Ｎａｂ1 및 ｎａｂ2의 약학 용도 Download PDF

Info

Publication number: KR20010071832A
Authority: KR; South Korea
Prior art keywords: nab1; nab2; polypeptide; nucleic acid; acid molecule
Prior art date: 1998-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020017000413A

Other languages

English (en)

Korean (ko)

Inventor

마틴 브래독

칼륨 제프레이 켐벨

Original Assignee

그레이엄 브레레톤, 레슬리 에드워즈

글락소 그룹 리미티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-11

Filing date

1999-07-09

Publication date

2001-07-31

1998-07-11 Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en

1998-09-12 Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en

1999-07-09 Application filed by 그레이엄 브레레톤, 레슬리 에드워즈, 글락소 그룹 리미티드 filed Critical 그레이엄 브레레톤, 레슬리 에드워즈

2001-07-31 Publication of KR20010071832A publication Critical patent/KR20010071832A/ko

Status Withdrawn legal-status Critical Current

Links

101000583053 Homo sapiens NGFI-A-binding protein 1 Proteins 0.000 title claims abstract description 89
102100030407 NGFI-A-binding protein 1 Human genes 0.000 title claims abstract description 88
101000583057 Homo sapiens NGFI-A-binding protein 2 Proteins 0.000 title claims abstract description 19
CZSLEMCYYGEGKP-UHFFFAOYSA-N N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide Chemical compound CC1=CC=C(C)C(N2C3=CC=C(C=C3N=C2)C(=O)NCC=2C(=CC=CC=2)Cl)=C1 CZSLEMCYYGEGKP-UHFFFAOYSA-N 0.000 title claims abstract description 19
102100030391 NGFI-A-binding protein 2 Human genes 0.000 title claims abstract 16
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 157
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 154
229920001184 polypeptide Polymers 0.000 claims abstract description 153
239000012634 fragment Substances 0.000 claims abstract description 63
150000007523 nucleic acids Chemical class 0.000 claims abstract description 36
102000039446 nucleic acids Human genes 0.000 claims abstract description 29
108020004707 nucleic acids Proteins 0.000 claims abstract description 29
238000004519 manufacturing process Methods 0.000 claims abstract description 19
230000029663 wound healing Effects 0.000 claims abstract description 18
241000124008 Mammalia Species 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
201000010099 disease Diseases 0.000 claims abstract description 15
230000002062 proliferating effect Effects 0.000 claims abstract description 15
230000014509 gene expression Effects 0.000 claims description 53
239000013598 vector Substances 0.000 claims description 50
238000000034 method Methods 0.000 claims description 48
230000004071 biological effect Effects 0.000 claims description 13
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 11
239000010931 gold Substances 0.000 claims description 11
229910052737 gold Inorganic materials 0.000 claims description 11
230000001225 therapeutic effect Effects 0.000 claims description 11
241000282412 Homo Species 0.000 claims description 9
108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
239000002245 particle Substances 0.000 claims description 8
238000001415 gene therapy Methods 0.000 claims description 7
206010023330 Keloid scar Diseases 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000037390 scarring Effects 0.000 claims description 4
102000044952 human NAB2 Human genes 0.000 claims description 3
230000001969 hypertrophic effect Effects 0.000 claims description 3
238000000053 physical method Methods 0.000 claims description 3
102000044448 human NAB1 Human genes 0.000 claims 2
208000002260 Keloid Diseases 0.000 claims 1
210000001117 keloid Anatomy 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 45
239000003814 drug Substances 0.000 abstract description 7
102000040430 polynucleotide Human genes 0.000 description 97
108091033319 polynucleotide Proteins 0.000 description 97
239000002157 polynucleotide Substances 0.000 description 96
210000004027 cell Anatomy 0.000 description 76
208000027418 Wounds and injury Diseases 0.000 description 66
206010052428 Wound Diseases 0.000 description 64
101100444898 Mus musculus Egr1 gene Proteins 0.000 description 50
108020004414 DNA Proteins 0.000 description 33
238000001890 transfection Methods 0.000 description 31
239000003102 growth factor Substances 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 25
235000018102 proteins Nutrition 0.000 description 25
230000000694 effects Effects 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 21
210000001519 tissue Anatomy 0.000 description 18
239000013604 expression vector Substances 0.000 description 17
230000035897 transcription Effects 0.000 description 16
238000013518 transcription Methods 0.000 description 16
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
230000001404 mediated effect Effects 0.000 description 14
230000004048 modification Effects 0.000 description 14
238000012986 modification Methods 0.000 description 14
125000003275 alpha amino acid group Chemical group 0.000 description 13
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
102000004887 Transforming Growth Factor beta Human genes 0.000 description 11
108090001012 Transforming Growth Factor beta Proteins 0.000 description 11
230000033115 angiogenesis Effects 0.000 description 11
238000011161 development Methods 0.000 description 11
239000000203 mixture Substances 0.000 description 11
108010000685 platelet-derived growth factor AB Proteins 0.000 description 11
230000004913 activation Effects 0.000 description 10
230000027455 binding Effects 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
230000018109 developmental process Effects 0.000 description 10
230000035876 healing Effects 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
241000700159 Rattus Species 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
241000700605 Viruses Species 0.000 description 8
238000007792 addition Methods 0.000 description 8
238000005755 formation reaction Methods 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
210000002615 epidermis Anatomy 0.000 description 7
239000013613 expression plasmid Substances 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
238000011065 in-situ storage Methods 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
241000283984 Rodentia Species 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000012010 growth Effects 0.000 description 6
230000004481 post-translational protein modification Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
231100000241 scar Toxicity 0.000 description 6
238000010186 staining Methods 0.000 description 6
-1 terminal amino acids Chemical class 0.000 description 6
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
208000032544 Cicatrix Diseases 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
201000004681 Psoriasis Diseases 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
230000008569 process Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000037387 scars Effects 0.000 description 5
230000014616 translation Effects 0.000 description 5
208000004434 Calcinosis Diseases 0.000 description 4
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
102100021866 Hepatocyte growth factor Human genes 0.000 description 4
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 4
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 4
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
230000002308 calcification Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
238000007887 coronary angioplasty Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
238000003365 immunocytochemistry Methods 0.000 description 4
238000012744 immunostaining Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000014674 injury Diseases 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
208000037803 restenosis Diseases 0.000 description 4
210000003705 ribosome Anatomy 0.000 description 4
230000036573 scar formation Effects 0.000 description 4
238000003307 slaughter Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000013519 translation Methods 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
230000002792 vascular Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102400001368 Epidermal growth factor Human genes 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
230000009702 cancer cell proliferation Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012761 co-transfection Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000006071 cream Substances 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
230000004927 fusion Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
229940040129 luteinizing hormone Drugs 0.000 description 3
239000013641 positive control Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000008719 thickening Effects 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
230000005030 transcription termination Effects 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
108010047303 von Willebrand Factor Proteins 0.000 description 3
102100036537 von Willebrand factor Human genes 0.000 description 3
230000005730 ADP ribosylation Effects 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
102100025947 Insulin-like growth factor II Human genes 0.000 description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
102000007999 Nuclear Proteins Human genes 0.000 description 2
108010089610 Nuclear Proteins Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006251 gamma-carboxylation Effects 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940068935 insulin-like growth factor 2 Drugs 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000006210 lotion Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000035772 mutation Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
108010017843 platelet-derived growth factor A Proteins 0.000 description 2
230000017363 positive regulation of growth Effects 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
229960005314 suramin Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
101150059401 EGR2 gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101000621344 Homo sapiens Protein Wnt-2 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
102100025169 Max-binding protein MNT Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
101100347652 Mus musculus Nab2 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100022805 Protein Wnt-2 Human genes 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010072170 Skin wound Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
208000005475 Vascular calcification Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000001354 calcination Methods 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000011712 cell development Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
238000011424 computer programming method Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
BDWFYHUDXIDTIU-UHFFFAOYSA-N ethanol;propane-1,2,3-triol Chemical compound CCO.OCC(O)CO BDWFYHUDXIDTIU-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
230000035558 fertility Effects 0.000 description 1
150000002211 flavins Chemical class 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000043827 human Smooth muscle Human genes 0.000 description 1
108700038605 human Smooth muscle Proteins 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000008692 neointimal formation Effects 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000010258 osteoblastogenesis Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000026341 positive regulation of angiogenesis Effects 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000010388 wound contraction Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Marine Sciences & Fisheries (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

KR1020017000413A 1998-07-11 1999-07-09 Ｎａｂ1 및 ｎａｂ2의 약학 용도 Withdrawn KR20010071832A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB9814989.1		1998-07-11
GBGB9814989.1A GB9814989D0 (en)	1998-07-11	1998-07-11	Gene therapy method
GB9819826.0		1998-09-12
GBGB9819826.0A GB9819826D0 (en)	1998-09-12	1998-09-12	Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (fr)	1998-07-11	1999-07-09	Utilisations pharmaceutiques de nab1 et nab2

Publications (1)

Publication Number	Publication Date
KR20010071832A true KR20010071832A (ko)	2001-07-31

Family

ID=26314007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020017000413A Withdrawn KR20010071832A (ko)	1998-07-11	1999-07-09	Ｎａｂ1 및 ｎａｂ2의 약학 용도

Country Status (22)

Country	Link
EP (1)	EP1097200A1 (fr)
JP (1)	JP2002520020A (fr)
KR (1)	KR20010071832A (fr)
CN (1)	CN1317045A (fr)
AP (1)	AP2001002038A0 (fr)
AU (1)	AU763713B2 (fr)
BR (1)	BR9912018A (fr)
CA (1)	CA2336805A1 (fr)
EA (1)	EA200100028A1 (fr)
EE (1)	EE200100020A (fr)
HR (1)	HRP20010025A2 (fr)
HU (1)	HUP0102835A3 (fr)
ID (1)	ID27742A (fr)
IL (1)	IL140533A0 (fr)
IS (1)	IS5788A (fr)
NO (1)	NO20010166L (fr)
NZ (1)	NZ509174A (fr)
PL (1)	PL345507A1 (fr)
SK (1)	SK382001A3 (fr)
TR (1)	TR200100622T2 (fr)
WO (1)	WO2000003014A1 (fr)
YU (1)	YU1901A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928430D0 (en) *	1999-12-01	2000-01-26	Glaxo Group Ltd	Screening
US6753321B2 (en)	2000-09-15	2004-06-22	Genvec, Inc.	Method of modulating neovascularization
WO2004083435A1 (fr) *	2003-03-17	2004-09-30	Julius-Maximilians-Uni Versität Würzburg	Proteines nab et leur utilisation dans des applications diagnostiques et therapeutiques de maladie cardiaque

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5036006A (en) *	1984-11-13	1991-07-30	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) *	1989-12-14	1997-12-16	Elof Eriksson	Gene delivery by microneedle injection

1999
- 1999-07-09 HR HR20010025A patent/HRP20010025A2/hr not_active Application Discontinuation
- 1999-07-09 PL PL99345507A patent/PL345507A1/xx not_active Application Discontinuation
- 1999-07-09 EE EEP200100020A patent/EE200100020A/xx unknown
- 1999-07-09 KR KR1020017000413A patent/KR20010071832A/ko not_active Withdrawn
- 1999-07-09 AP APAP/P/2001/002038A patent/AP2001002038A0/en unknown
- 1999-07-09 EP EP99931378A patent/EP1097200A1/fr not_active Withdrawn
- 1999-07-09 JP JP2000559235A patent/JP2002520020A/ja active Pending
- 1999-07-09 HU HU0102835A patent/HUP0102835A3/hu unknown
- 1999-07-09 TR TR2001/00622T patent/TR200100622T2/xx unknown
- 1999-07-09 BR BR9912018-6A patent/BR9912018A/pt not_active IP Right Cessation
- 1999-07-09 IL IL14053399A patent/IL140533A0/xx unknown
- 1999-07-09 ID IDW20010345A patent/ID27742A/id unknown
- 1999-07-09 CA CA002336805A patent/CA2336805A1/fr not_active Abandoned
- 1999-07-09 NZ NZ509174A patent/NZ509174A/en unknown
- 1999-07-09 YU YU1901A patent/YU1901A/sh unknown
- 1999-07-09 AU AU47914/99A patent/AU763713B2/en not_active Ceased
- 1999-07-09 SK SK38-2001A patent/SK382001A3/sk unknown
- 1999-07-09 WO PCT/GB1999/002199 patent/WO2000003014A1/fr not_active Ceased
- 1999-07-09 CN CN99810616A patent/CN1317045A/zh active Pending
- 1999-07-09 EA EA200100028A patent/EA200100028A1/ru unknown
2000
- 2000-12-22 IS IS5788A patent/IS5788A/is unknown
2001
- 2001-01-10 NO NO20010166A patent/NO20010166L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR200100622T2 (tr)	2001-10-22
JP2002520020A (ja)	2002-07-09
AP2001002038A0 (en)	2001-03-31
CN1317045A (zh)	2001-10-10
HUP0102835A3 (en)	2003-09-29
BR9912018A (pt)	2006-01-31
NZ509174A (en)	2003-08-29
HUP0102835A2 (hu)	2001-11-28
PL345507A1 (en)	2001-12-17
CA2336805A1 (fr)	2000-01-20
WO2000003014A1 (fr)	2000-01-20
IS5788A (is)	2000-12-22
EE200100020A (et)	2002-06-17
NO20010166L (no)	2001-03-06
AU763713B2 (en)	2003-07-31
YU1901A (sh)	2005-06-10
EP1097200A1 (fr)	2001-05-09
EA200100028A1 (ru)	2001-08-27
HRP20010025A2 (en)	2001-12-31
IL140533A0 (en)	2002-02-10
AU4791499A (en)	2000-02-01
SK382001A3 (en)	2001-09-11
NO20010166D0 (no)	2001-01-10
ID27742A (id)	2001-04-26

Publication	Publication Date	Title
EP1083934B1 (fr)	2003-08-06	EGR-1 pour la fabrication d'un médicament pour le traitement des blessures
AU2006268091B2 (en)	2010-09-02	Promotion of epithelial regeneration
US20030103956A1 (en)	2003-06-05	Use of HIF-1a variants to accelerate wound healing
KR20010071832A (ko)	2001-07-31	Ｎａｂ1 및 ｎａｂ2의 약학 용도
MXPA01000386A (en)	2001-11-21	Pharmaceutical uses of nab1 and nab2
CZ2001142A3 (cs)	2001-06-13	Použití molekuly nukleové kyseliny
ZA200100193B (en)	2002-01-08	Pharmaceutical uses of NAB1 and NAB2.
HK1034465B (en)	2004-01-30	Egr-1 for the manufacture of a medicament for treating wounds
US20240181125A1 (en)	2024-06-06	Compositions and methods for scarless wound healing in diabetes
HK1050914A (en)	2003-07-11	Early growth response-1 (egr-1) transcription factor
US8748568B2 (en)	2014-06-10	Isolated A-type FHF N-terminal domain peptides and methods of use
ZA200006963B (en)	2002-01-02	Gene therapy method.
WO2002020609A2 (fr)	2002-03-14	Nouvelle utilisation
CZ20004509A3 (cs)	2001-07-11	Způsob genové terapie
MXPA00011726A (en)	2001-11-21	Gene therapy method
Henry	2003	Biolistic augmentation of wound healing in diabetic and steroid treated rats
US20030092030A1 (en)	2003-05-15	Wit 3.0, a novel gene to control soft tissue wound healing
KR20110095611A (ko)	2011-08-25	Ｍｉｃ―１ 유전자 또는 그의 발현 단백질을 함유하는 상처 치료용 약학적 조성물

Legal Events

Date	Code	Title	Description
2001-01-10	PA0105	International application	Patent event date: 20010110 Patent event code: PA01051R01D Comment text: International Patent Application
2001-07-31	PG1501	Laying open of application
2004-07-10	PC1203	Withdrawal of no request for examination
2004-07-10	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid